| pubmed-article:1385350 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1385350 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1385350 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
| pubmed-article:1385350 | lifeskim:mentions | umls-concept:C0010031 | lld:lifeskim |
| pubmed-article:1385350 | lifeskim:mentions | umls-concept:C0623362 | lld:lifeskim |
| pubmed-article:1385350 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:1385350 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:1385350 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:1385350 | pubmed:dateCreated | 1992-12-17 | lld:pubmed |
| pubmed-article:1385350 | pubmed:abstractText | Healing of corneal alkali injuries remains a severe clinical challenge. The authors evaluated the effect of a new synthetic inhibitor of matrix metalloproteinases (GM6001 or N-[2(R)-2-(hydroxamido carbonylmethyl)-4-methylpentanoyl]-L-tryptophane methylamide) on preventing ulceration of rabbit corneas after alkali injury. Topical treatment of corneas with severe alkali injuries with 400 micrograms/ml or 40 micrograms/ml GM6001 alone prevented ulceration for 28 days, although 8 of 10 corneas treated with vehicle perforated. Corneas treated with 4 micrograms/ml GM6001 had midstromal depth ulcers. Corneas treated with 400 micrograms/ml of GM6001 contained very few inflammatory cells and had significantly reduced vessel ingrowth compared with vehicle-treated corneas. Epithelial regeneration after moderate alkali injuries also was investigated. Persistent epithelial defects developed 4 days after moderate alkali injury in rabbit corneas treated with vehicle and progressively increased to an average of 20% of the original 6 mm diameter wound by 27 days after moderate alkali injury. By contrast, epithelial regeneration was complete and persisted for 21 days for corneas treated with a formulation containing GM6001 (400 micrograms/ml), epidermal growth factor (10 micrograms/ml), fibronectin (500 micrograms/ml), and aprotinin (400 micrograms/ml). Sporadic punctate staining developed in 20% of the corneas treated with the combination of agents between days 21-28 after moderate alkali injury. These results demonstrate that topical application of GM6001 prevented corneal ulceration after severe alkali injury and that a combination containing GM6001, epidermal growth factor, fibronectin, and aprotinin promoted stable regeneration of corneal epithelium after moderate alkali injury. | lld:pubmed |
| pubmed-article:1385350 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1385350 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1385350 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1385350 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1385350 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:1385350 | pubmed:issn | 0146-0404 | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:GalardyR ERE | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:RowseyJ JJJ | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:SchultzG SGS | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:StrelowSS | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:SternG AGA | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:CheginiNN | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:GrobelnyDD | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:GrantM BMB | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:StonecipherKK | lld:pubmed |
| pubmed-article:1385350 | pubmed:author | pubmed-author:ParmleyVV | lld:pubmed |
| pubmed-article:1385350 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1385350 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:1385350 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1385350 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1385350 | pubmed:pagination | 3325-31 | lld:pubmed |
| pubmed-article:1385350 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:meshHeading | pubmed-meshheading:1385350-... | lld:pubmed |
| pubmed-article:1385350 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1385350 | pubmed:articleTitle | Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases. | lld:pubmed |
| pubmed-article:1385350 | pubmed:affiliation | Department of Obstetrics and Gynecology, University of Florida, Gainesville 32610. | lld:pubmed |
| pubmed-article:1385350 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1385350 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1385350 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1385350 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1385350 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1385350 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1385350 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1385350 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1385350 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1385350 | lld:pubmed |
